Drug Profile
Research programme: p53 targeted cancer therapeutics - Eleos
Alternative Names: Antisense p53 therapeutics - EleosLatest Information Update: 18 Jul 2012
Price :
$50
*
At a glance
- Originator Eleos
- Class Antisense elements
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 18 Jul 2012 No development reported - Preclinical for Cancer in USA (unspecified route)
- 12 Jul 2012 AVI Biopharma is now called Sarepta Therapeutics
- 31 Dec 2008 The collaboration with Eleos and AVI BioPharma is still active